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Summary
Objective: To evaluate interrater agreement in categorizing treatment outcomes
and drug responsiveness status according to the International League Against Epi-
lepsy (ILAE) definition of drug‐resistant epilepsy.
Methods: A total of 1053 adults with focal epilepsy considered by the investiga-
tors to meet ILAE criteria for drug resistance were enrolled consecutively at 43
centers and followed up prospectively for 18‐34 months. Treatment outcomes for
all antiepileptic drugs (AEDs) used up to enrollment (retrospective assessment),
and on an AED newly introduced at enrollment, were categorized by individual
investigators and by 2 rotating members of a 16‐member expert panel (EP) that
reviewed the patient records independently. Interrater agreement was tested by
Cohen’s kappa (k) statistics and rated according to Landis and Koch’s criteria.
Results: Agreement between EP members in categorizing outcomes on the newly
introduced AED was almost perfect (90.1%, k = 0.84, 95% confidence interval
[CI] 0.80‐0.87), whereas agreement between the EP and individual investigators
was moderate (70.4%, k = 0.57, 95% CI 0.53‐0.61). Similarly, categorization of
outcomes on previously used AEDs was almost perfect between EP members
(91.7%, k = 0.83, 95% CI 0.81‐0.84) and moderate between the EP and investiga-
tors (68.2%, k = 0.50, 95% CI 0.48‐0.52). Disagreement was related predomi-
nantly to outcomes considered to be treatment failures by the investigators but
categorized as undetermined by the EP. Overall, 19% of patients classified as hav-
ing drug‐resistant epilepsy by the investigators were considered by the EP to have
“undefined responsiveness.”
Significance: Interrater agreement in categorizing treatment outcomes according
to ILAE criteria ranges from moderate to almost perfect. Nearly 1 in 5 patients
considered by enrolling neurologists to be “drug‐resistant” were classified by the
EP as having “undefined responsiveness.”
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1 | INTRODUCTION
Although there is general agreement that drug resistance is
a major challenge in the management of epilepsy, defini-
tions of pharmacoresistance used in past decades have dif-
fered widely across studies.1,2 To promote the use of
common concepts and a common language, in 2009 the
International League Against Epilepsy (ILAE) Task Force
proposed to define drug resistance as “failure of adequate
trials of two tolerated and appropriately chosen and used
antiepileptic drug (AED) schedules (whether as monothera-
pies or in combination) to achieve sustained seizure free-
dom.”3 The assessment of the possible outcomes of an
intervention (seizure‐free, treatment failure, and undeter-
mined) by ILAE criteria is largely conceptual,4 and the cat-
egorization process needs to be operationalized to
determine when a therapeutic trial is “appropriate” (selec-
tion of AED based on seizure and patient characteristics)
and “adequate” (including good tolerance, optimal dosing
schedules, drug adherence and duration of exposure). In sit-
uations where appropriateness and adequacy cannot be
assessed or satisfied, the outcome is deemed as “undeter-
mined.”5 The ILAE categorization scheme is increasingly
being applied worldwide in studies on drug‐resistant
epilepsy.6,7
The ILAE Task Force emphasized that the proposed
definition should be regarded as a “working framework”
and that prospective validation studies should be encour-
aged. Based on these premises, a large prospective study
was initiated in 2011 with the following 2 main objec-
tives: (a) to assess outcomes on a newly introduced AED
treatment in adults meeting ILAE criteria for drug‐resis-
tant focal epilepsy and (b) to test interrater variability
among neurologists in applying ILAE criteria for catego-
rizing treatment outcomes and drug resistance status. To
investigate the reliability of the ILAE definition, this
study involved a comparison of the categorization of out-
comes made by individual neurologists with that made
by an external expert panel (EP), as well as a compar-
ison of level of agreement between EP members. The
results of this comparison represent the focus of this
article.
2 | METHODS
2.1 | Study design, eligibility criteria, and
study procedures
Data were drawn from a large multicenter, observational,
prospective study of adults with drug‐resistant focal epi-
lepsy recruited in 43 epilepsy centers in Italy (Appendix)
between 2011 and 2015, aimed at investigating treatment
outcomes after introduction of another (additional or substi-
tuted) AED (Prometeo study SP0992).8 Patients were
enrolled consecutively according to the following criteria:
age 18 years or older; an established diagnosis of focal epi-
lepsy; a diagnosis of drug resistance made by the enrolling
physician according to ILAE criteria3; an interseizure inter-
val not exceeding 6 months in the 12 months preceding
enrollment; being on AED treatment with a clinical indica-
tion to modify existing therapy by introducing another
AED, either as add‐on or in substitution, in a combination
not previously used.
Prior to initiation of enrollment, investigators partici-
pated in an ad hoc interactive meeting to ensure that all
were familiar with the ILAE definition of drug resistance
and with the variables needed to categorize patients. It was
emphasized that, in accordance with the observational nat-
ure of the study, treatments had to be prescribed according
Key Points
• Interrater agreement in categorizing treatment
outcomes by ILAE criteria is moderate to almost
perfect, being dependent on the expertise of indi-
vidual raters
• Based on an EP’s assessment, 1 in 5 patients
considered to be drug resistant by the treating
neurologists actually have undefined responsive-
ness
• There is a need to have a better understanding of
the ILAE definition of drug resistance, and to
take a more critical approach to evaluating treat-
ment outcomes
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to good medical practice and that, in particular, adequacy of
dosing schedules had to be assessed based on clinical judge-
ment, using the World Health Organization (WHO) defined
daily dose as a rough reference only.3 To determine whether
potentially eligible patients fulfilled ILAE criteria for drug
resistance, investigators assessed outcomes of all previously
administered treatments based on clinical records and an
interview with the patient. Dosages of the newly introduced
AED and other medications were adjusted as clinically indi-
cated, and the outcome of the treatment introduced at
enrollment was evaluated prospectively according to ILAE
criteria. Patients were assessed at time 0 (baseline) and at 6,
12, and 18 months, or more frequently if clinically indi-
cated. An additional visit was scheduled for patients who
had been seizure‐free for at least 60 days at the 18‐month
visit but had not yet met ILAE criteria for seizure freedom.
In these patients, follow‐up could be extended for up to an
additional 16 months to provide sufficient time to establish
whether seizure freedom had been achieved.
The study was conducted in compliance with Good
Clinical Practice guidelines ICH. Approval was obtained
from ethics committees of all participating centers, and
written informed consent was obtained from each patient.
Information recorded in the electronic case report forms
(eCRFs) included demographic and disease‐related charac-
teristics, outcome data (reported in a separate publication8),
and treatment details (dosing schedules, titration rates, and
serum drug concentrations, when available) for each AED
and other drugs used by the patient in the past and
throughout the study.
2.2 | Role of the expert panel (EP)
An expert panel (EP) composed of 16 experienced epilep-
tologists, not involved in the enrollment or management of
study patients or in the compilation of eCRFs at local sites,
reviewed all eCRFs to confirm or refute the investigators’
categorization of the outcome of each AED trial applied
before enrollment (retrospective categorization) and of the
AED newly introduced at enrollment (prospective catego-
rization), as well as the categorization of each patient’s
drug responsiveness/resistance status. Before initiation of
the reviewing process, each EP member categorized treat-
ment outcomes in a sample of 30 eCRF obtained from a
separate set of patients, and the results of this review were
compared in a meeting of all EP members in order to dis-
cuss the correct criteria of categorization.
Each eCRF was reviewed separately and independently by
2 EP members chosen in a random and blinded manner by an
automated computerized system. In no case did the system
assign an eCRF to an expert from an institution at which that
patient was enrolled. The computerized system selected a fresh
expert pair at each assignment, and each expert was assigned
eCRFs from different centers. Experts performed their evalua-
tions without knowledge of the identity of the other expert
included in the review of the same eCRF, but in case of dis-
agreement, the computer informed the members of the EP pair
that a discrepancy had occurred. At that point, the evaluation
of that eCRF was unblinded and the EP pair was requested to
communicate and resolve the disagreement. If the disagreement
was not resolved, the chair of the EP reviewed the case and
made a final categorization. Because the overall framework of
the ILAE definition is comprised of 2 “hierarchical” levels, that
is, determination of outcome of each AED trial (level 1) and
determination of drug resistance/responsiveness status (level
2), both categorization levels were reviewed. Wherever the
members of the EP disagreed with the investigator’s catego-
rization, the reason for disagreement had to be specified.
2.3 | Statistical analysis
Interrater agreement in categorizing the outcome of each
drug trial (level 1) was evaluated between experts, both
before and after communication, as well as between the EP
and investigators. This analysis was performed separately
for retrospective data (all treatments used in the past,
including those present at the time of enrolment) and
prospective data (outcome of the treatment introduced at
enrollment). Analysis was focused on the 3 main outcomes
(seizure freedom, treatment failure, undetermined). Inter-
rater agreement on the presence/absence of adverse effects
(an additional component of the ILAE categorization) was
virtually negligible and was not analyzed.
Descriptive statistics (means, frequencies, and propor-
tions) were used to characterize demographic and clinical
variables. The Cohen kappa (k) statistical method was used
to assess interrater agreement and was interpreted according
to the criteria of Landis and Koch,9 as follows: ≤0, poor
agreement; 0.01‐0.2, slight agreement; 0.21‐0.4, fair agree-
ment; 0.41‐0.6, moderate agreement; 0.61‐0.8, substantial
agreement; and 0.81‐1, almost perfect agreement.
3 | RESULTS
3.1 | Characteristics of the study population
The main characteristics of the study population are shown
in Table 1. Each of the 1053 recruited patients had a trial
on a newly introduced AED, which was prospectively eval-
uated. Patients had a median seizure frequency of 5 sei-
zures per month prior to entry into the study and were
taking an average of 2.1 AEDs at enrollment. The total
number of AED trials evaluated at enrollment (previous
and ongoing AEDs at enrolment) was 5725. One hundred
seventy‐two trials (3%) were not evaluated and were
excluded from the current analysis. These trials were made
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with fixed‐dose combination AED products or with obso-
lete active principles that are no longer available.
3.2 | Interrater agreement in categorizing
outcomes on the newly introduced drug (level 1)
The level of agreement between members of the EP and
between the EP and investigators in categorizing treatment
outcomes on the newly introduced AED (prospective
assessment) is summarized in Table 2. The agreement
between EP members after initial blind evaluation was
almost perfect, with concordant categorizations being
reported in 954 of 1053 cases (90.1%, k = 0.84, 95% confi-
dence interval [CI] 0.80‐0.87), and improving further after
EP members communicated to solve discrepancies (96.3%,
k = 0.94, 95% CI 0.92‐0.96). The magnitude of the agree-
ment between the EP and individual investigators was
moderate (70.4%, k = 0.57, 95% CI 0.53‐0.61), with EP
and investigators failing to agree in 312 of 1053 cases
(29.6%). In the majority of cases, outcomes that were con-
sidered by investigators as “treatment failures” (242/642,
38%) or as “seizure freedom” (14/92, 15%) were classified
by the EP as “undetermined.” Conversely, of 315 outcomes
categorized as “undetermined” by investigators, 55 (17%)
were recategorized by the EP as “treatment failures” and 3
(1%) were classified as “seizure‐free.”
With respect to the most common causes of disagree-
ment, in almost two‐thirds of the cases, members of the EP
panel considered the maximum AED dose attained as
insufficient to justify a categorization as “treatment failure”
(Table 3). Inadequate dosing was also the most frequent
cause of disagreement between members of the EP, both at
initial assessment and after communication.
Overall, treatment outcome on the newly introduced
AED was categorized as a “treatment failure” in 646 cases
(61.3%) by the investigators, and in 452 cases (43%) by
the EP. Outcome was classified as “undetermined” in 315
cases (29.9%) according to the investigators, and in 517
cases (49.1%) according to the EP. Details of treatment
outcomes on the newly introduced AED and associated
variables are reported in a separate publication.8
The agreement between members of the EP and
between the EP and investigators in categorizing treatment
outcomes was also evaluated for the 5725 retrospective
AED trials (eg, trials with previously used AEDs and with
AEDs already in use at enrollment; Table 4). Similar to the
findings of the prospective assessment, while the agreement
between EP members at initial evaluation was almost per-
fect (91.7%, k = 0.83, 95% CI 0.81‐0.84) and improved
further after communication between experts (95.9%,
k = 0.91, 95% CI 0.90‐0.92), the categorization of the EP
differed from that of the investigator in 31.8% of cases,
which corresponds to a moderate level of agreement
(k = 0.50, 95% CI 0.48‐0.52). The most common disagree-
ment consisted in the EP recategorizing outcomes that had
been considered “treatment failures” by the investigator
(1689/4786, 35.3%) as “undetermined.” In a small number
of cases, outcomes were reclassified from “seizure‐free” to
TABLE 1 Clinical characteristics of the patients enrolled in the
study
Age (y) 44.5 ± 14.2
Gender, male/female 504/549
Age at epilepsy onset (y) 18.1 ± 9.7
Duration of the epilepsy (y) 23.3 ± 15.2
Seizure frequency (per 28 days) in the 6 months prior to enrollment
(median and range)
All seizures (n = 1053) 5 (0.1‐220)
Focal aware seizures (n = 359) 4 (0.1‐180)
Focal impaired awareness seizures (n = 765) 4 (0.1‐180)
Focal to bilateral tonic–clonic seizures (n = 326) 1 (0.1‐45)
Number of AEDs taken at enrollment 2.1 ± 0.8

























89 444 481 39 0.94 (0.92‐0.96)
TABLE 2 Level of agreement
between investigators and EP, and
between EP members, in categorizing
outcomes on a newly introduced AED
(prospective assessment) in the 1053
patients included in the study
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“undetermined” (19/77, 24.7%) or from “undetermined” to
“treatment failure” (107/862, 12.4%). As reported for the
prospective assessment, use of AED doses considered to be
adequate by the investigator and to be insufficient by the
EP was the most common reason for disagreement (46% of
cases) and was followed by lack of adequate information
(41% of cases). The latter was also the most common cause
of disagreement between EP members.
3.3 | Interrater agreement in categorizing
drug‐resistance status (level 2)
Figure 1 illustrates the distribution of the number of previ-
ous AED failures for the 1053 patients at the time of
enrollment, as categorized by the investigators and by the
EP, respectively. All patients were categorized by the
investigators as being drug resistant, even though in 4
cases (0.004%) the minimum requirement (2 AED fail-
ures) was not met. The number of previous AED failures
based on EP categorization was lower than that deter-
mined by the investigators. As a result of this reclassifica-
tion, 203 patients (19% of the entire cohort) were
determined by the EP as having failed fewer than 2 AEDs
and, as a result, were not considered by the EP as being
drug resistant per ILAE criteria and were thus recatego-
rized as “undefined.”
Disagreement between the EP and investigators in clas-
sifying drug resistance after the prospective trial is influ-
enced by the number of treatment failures categorized at
TABLE 3 Main reasons for disagreement in categorizing the
outcome of the therapeutic intervention applied at enrollment in the


























56 (8.9%) 23 (8%) 10 (11%)
Inappropriate
AED choice









6 (0.9%) 2 (0.7%) ‐
Insufficient
AED dose
396 (63%) 173(62%) 57 (65%)
Other (not
specified)
161 (25%) 75 (27%) 15 (17%)
n, total number of reasons for which there was disagreement. Each of the 2
members of the EP may have expressed a different reason for disagreement
and therefore the number of reasons may exceed the number of disagreements
in the categorization of outcomes.
TABLE 4 Level of agreement
between investigators and EP, and
between EP members, in categorizing
the outcome of 5725 individual AED






















51 3150 2287 237 0.91 (0.90‐0.92)
FIGURE 1 Distribution of number of previously failed AEDs at
the time of enrollment among the 1053 patients included in the study,
as determined by the investigators and by the EP, respectively
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enrollment, and therefore will not be reported in detail.
Briefly, seizure freedom status was achieved at the end of
the study in 92 patients (8.7%) as determined by investiga-
tors, and in 84 patients (8%) as determined by the EP. Of
interesting, of the 92 patients classified as seizure‐free by
the investigators, 19 had been reclassified by the EP as
having “undefined” drug responsiveness at enrollment.
4 | DISCUSSION
Before the present study, 2 separate investigations evaluated
interrater reliability in applying the ILAE definition of drug‐
resistant epilepsy.2,10 Both studies included a relatively
small number of patients (≤150) with any type of epilepsy
and with different AED responsiveness, and they were based
on assessment of medical records by 2 independent evalua-
tors. In the pilot study by Hao et al,10 interrater agreement
in categorizing drug‐responsiveness status (level 2) was
excellent (k = 0.91), whereas in the study by Tellez‐Zenteno
et al,2 the level of agreement was inferior (k = 0.77), but
still satisfactory and better than that observed for other pre-
viously used definitions of drug resistance.
The present investigation differed from previously
conducted studies in several ways: (a) it included a much
larger cohort of consecutively enrolled patients; (b) it
focused on adults with focal epilepsy diagnosed by investi-
gators as drug resistant; (c) it included not only a retrospec-
tive assessment based on medical records, but also a
prospective assessment of the outcome of a therapeutic
intervention applied at enrollment, with a prolonged (up to
34‐months) duration of follow‐up; and (d) interrater agree-
ment was not based on assessment by 2 evaluators but on
a comparison between categorizations made by individual
investigators at the 43 enrolling centers and by an external
EP, as well as between rotating members of EP pairs.
At enrollment, the overall agreement between investiga-
tors and the EP in classifying epilepsy as drug resistant
was 80%, which is relatively good and close to the level of
agreement reported by Tellez‐Zenteno et al2 in a more
heterogeneous patient group. However, agreement in the
level 1 categorization was lower, with a disagreement of
~30% for the prospective assessment and ~32% for the ret-
rospective assessment.
Our findings have several practical implications. First,
they demonstrate that interrater reliability in assessing treat-
ment outcomes ranges from moderate to almost perfect,
being highly dependent on the judgment of individual physi-
cians. Specifically, the level of agreement between different
EP members in the blinded assessment of both retrospective
(k = 0.83) and prospective (k = 0.84) AED trials was much
greater than the level of agreement between the EP and indi-
vidual investigators (k = 0.57 for prospective drug trials;
k = 0.50 for retrospective trials). This observation seems to
reflect a more conservative approach of EP members in cate-
gorizing the outcome of a therapeutic intervention, both in
the retrospective and prospective phases of the study. In fact,
in the large majority of cases, disagreement consisted of the
EP categorizing as “undetermined” outcomes that had been
deemed to be “treatment failures” by the enrolling physi-
cians. The primary causes of disagreement were the EP’s
determination that data were not sufficiently informative or
that the maximal dose achieved was insufficient to consider
the trial as adequate. It should be emphasized that application
of ILAE criteria is dependent on subjective interpretation of
clinical data and, therefore, some degree of individual vari-
ability in interpretation is expected. Our findings suggest that
a critical determinant of disagreement in interpretation, not
only between investigators and the EP, but also between EP
members, is the dosage of a drug that should be tried before
a treatment can be considered to have failed. The ILAE con-
sensus paper states that “for adults, reference may be made
to the WHO’s defined daily dose,” and that “there should be
a documented attempt to titrate the dose to a target clinically
effective dose range,” but it does not go as far as recom-
mending that, in patients with persisting seizures, an attempt
should be made to reach the highest tolerated dose.3 Inevita-
bly, physicians’ attitudes toward increasing dosage beyond
certain limits differ, and there are also inconsistencies in the
way clinicians use serum AED levels as a guide to dosage
adjustments. Finally, individual patient characteristics and
patients’ attitudes may affect a prescriber’s decision not to
increase dosage beyond a certain limit. At least to some
extent, these considerations may explain the apparent dis-
crepancies between investigators and the EP in determining
which dosages could be regarded as sufficient to categorize
an outcome as a treatment failure.
A second important message from our study is that an
appreciable number of patients considered to be drug resis-
tant in general clinical practice do not meet the criteria for
drug resistance after critical reevaluation of available infor-
mation. In fact, 1 of 5 patients enrolled by investigators
with a diagnosis of drug resistance were not deemed to
meet criteria for drug resistance by the EP. Despite the sub-
jective limitations of categorizing treatment outcomes, these
data suggest that drug resistance may be overdiagnosed in
clinical practice. Similar findings have been reported by
other investigators, suggesting that the condition known as
“pseudo‐pharmacoresistance” is more common than gener-
ally recognized.1,11 In a study from Spain, only 13 of 40
consecutive patients admitted to an epilepsy unit for presur-
gical evaluation met the criteria for drug resistance, and
70% of AED trials previously applied in those patients
were considered uninformative.12 The authors concluded
that adequate information on the implications of the ILAE
definition “should be spread among general neurologists
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for earlier and more complete referrals.” Before enrollment
in our study, all enrolling physicians underwent a training
session on the correct application of the definition, but this
did not prevent a probable suboptimal categorization of
many therapeutic outcomes. Overall, these data suggest that
greater efforts should be directed at training physicians on
how to critically interpret the outcome of therapeutic inter-
ventions. Our findings also suggest that future studies
specifically aimed at evaluating different aspects of drug
resistance may benefit from including an independent
external panel in order to validate, or at least confirm, the
diagnosis made by enrolling physicians.
A third message emerging from our results relates to the
outcome of the prospective evaluation. A detailed analysis of
responses to the newly administered AEDs in relation to the
number of previous treatment failures and other individual
characteristics is described in a sister publication.8 However,
a comment is required on the fact that about 8% of patients
confirmed by the EP to be drug resistant at enrollment
achieved seizure freedom on a newly administered treatment.
This finding supports the validity of the ILAE definition, in
that it confirms that for patients fulfilling the criteria for drug
resistance “the probability of achieving seizure freedom with
subsequent AED treatments is modest.”3 These data also
reinforce the concept that drug resistance is not synonymous
with medical intractability, and that some patients can
respond to treatment even after failing several AEDs.3 In this
respect, it should be stressed that our patients had tried more
than 5 AEDs in the past and that they represent a subpopula-
tion of more difficult‐to‐treat patients. Moreover, only one
new AED treatment was tried in the intervention, and a few
other patients could respond to additional drug trials. To
what extent seizure freedom in these patients can be main-
tained indefinitely is uncertain, because many types of epi-
lepsy seem to follow a relapse‐remitting pattern.13 The
relapsing nature of many types of epilepsy is confirmed by
our observation that an appreciable proportion of patients
considered drug resistant at enrollment had experienced peri-
ods of seizure freedom in the past.
Our study has limitations. First, drug resistance was
diagnosed at enrollment by assessing retrospectively out-
comes in patients with longstanding epilepsy who had tried
on average 5.6 medications, and diagnostic accuracy would
be expected to be greater in patients followed up prospec-
tively since diagnosis. Second, inclusion criteria were lim-
ited to patients who were considered drug resistant, and
only those were reassessed. It is likely that there were other
patients, initially not considered drug resistant, that on a
formal reassessment as in this study would meet criteria for
drug resistance. Third, the study was conducted at sec-
ondary and tertiary referral centers, and all participating
investigators were neurologists experienced in the manage-
ment of epilepsy. Therefore, our results cannot be
extrapolated to other settings and particularly to the pri-
mary care setting where variability in clinical management
and in the application of the ILAE definition may be
greater. Finally, our study only enrolled adults with focal
epilepsy, which ensured assessment of a relatively homoge-
nous population but also prevented inclusion of certain epi-
lepsy syndromes of infancy and childhood, where pseudo‐
drug resistance due to inappropriate AED choice is more
likely to occur.14
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